Back to search

Article

Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expression

2025-08-08

Abstract excerpt

<title>Abstract</title> <p> Background High programmed death-ligand 1 (PD-L1) expression represents a clinically meaningful improvement in survival benefit after administration of immune checkpoint inhibitors (ICIs). It remains that only a minority of patients with PD-L1 high expression demonstrate durable response in a real-life setting. The study aimed to explore the correlation between dynamic changes of lymp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1352af68-9756-5cec-81c4-9f1b9a5f5b31
DOI
10.21203/rs.3.rs-6915095/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expressionDOI 10.21203/rs.3.rs-6915095/v1
Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity
TCF-1+ PD-1+ CD8+T Cells Are Associated With The Response To PD-1 Blockade In Non-Small Cell Lung Cancer PatientsSemantic proximity
TP53 Mutation and Tumor-Infiltrating Lymphocytes as Predictors of PD-1/PD-L1 Inhibitor Efficacy in PD-L1-High Advanced NSCLC.Semantic proximity
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity
Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity
Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity
Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatmentSemantic proximity
Association of Lymphocyte Subsets in Advanced Non-Small Cell Lung Cancer Patients with the Efficacy and Prognosis of Immune Checkpoint Inhibitor Therapy: A Retrospective StudySemantic proximity
Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity
P53 and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS≥50%) defined by 22C3Semantic proximity
Select a neighboring publication to make it the new centre.